Anagrelide - CAS 68475-42-3
Catalog number: 68475-42-3
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C10H7Cl2N3O
Molecular Weight:
256.09
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
Anagrelide is a phosphodiesterase inhibitor with antiplatelet activity with IC50 value of 36 nM for inhibition of phosphodiesterase 3. It inhibits the maturation of megakaryocytes into platelets, reducing both megakaryocyte hyperproliferation and differentiation. It is antithrombocythemic used for the treatment of overproduction of blood platelets. It is a synthetic quinazoline derivative and is used as is a platelet-reducing agent. It reduces platelet production through a decrease in megakaryocyte maturation. It inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. It is a drug used for the treatment of essential thrombocytosis or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia. It was developed by Shire and has been listed.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Ivory powder
Synonyms:
6,7-Dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one;6-Chloro-1,2,3,5-tetrahydro iMidazo [2,1-b]quinazolin-2-one;Agrelin;Agrylin;Xagrid;Shire;Thromboreductin
Solubility:
Soluble in DMSO, not in water
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Anagrelide is used for the treatment of overproduction of blood platelets. It is a drug used for the treatment of essential thrombocytosis or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.
Quality Standard:
In-house standard
Quantity:
Kilograms to Tons
Boiling Point:
376.5°C at 760 mmHg
Melting Point:
280 °C
Density:
1.77±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
OTBXOEAOVRKTNQ-UHFFFAOYSA-N
InChI:
InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
Canonical SMILES:
C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31
Current Developer:
Anagrelide was developed by Shire and has been listed.
1.Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S1, Tefferi A1. Blood Cancer J. 2015 Nov 13;5:e366. doi: 10.1038/bcj.2015.95.
Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-ABL1-negative myeloproliferative neoplasms and are characterized by relatively long median survivals (approximately 14 and 20 years, respectively). Potentially fatal disease complications in PV and ET include disease transformation into myelofibrosis (MF) or acute myeloid leukemia (AML). The range of reported frequencies for post-PV MF were 4.9-6% at 10 years and 6-14% at 15 years and for post-ET MF were 0.8-4.9% at 10 years and 4-11% at 15 years. The corresponding figures for post-PV AML were 2.3-14.4% at 10 years and 5.5-18.7% at 15 years and for post-ET AML were 0.7-3% at 10 years and 2.1-5.3% at 15 years. Risk factors cited for post-PV MF include advanced age, leukocytosis, reticulin fibrosis, splenomegaly and JAK2V617F allele burden and for post-ET MF include advanced age, leukocytosis, anemia, reticulin fibrosis, absence of JAK2V617F, use of anagrelide and presence of ASXL1 mutation.
2.Influence of platelet and white blood cell counts on major thrombosis - Analysis from a patient registry in Essential Thrombocythemia.
Buxhofer-Ausch V1,2, Steurer M3, Sormann S4, Schloegl E5, Schimetta W6, Gisslinger B1, Ruckser R7, Gastl G3, Gisslinger H1. Eur J Haematol. 2016 Apr 1. doi: 10.1111/ejh.12759. [Epub ahead of print]
OBJECTIVES: Although guidelines recommend normalization of platelet counts as an appropriate endpoint for treatment in high-risk essential thrombocythemia (ET), retrospective studies could not prove a correlation of diagnostic platelet counts with an increased thrombotic rate. There is, however, an increasing evidence that leukocytosis is an important risk factor for arterial thrombosis in myeloproliferative neoplasms.
3.Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D1, Mascarenhas J. Curr Opin Hematol. 2016 Mar;23(2):150-60. doi: 10.1097/MOH.0000000000000216.
PURPOSE OF REVIEW: Management of polycythemia vera and essential thrombocythemia requires understanding of the key concepts regarding diagnosis, risk stratification, and management.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 324572-93-2 T 0156 hydrochloride

T 0156 hydrochloride
(CAS: 324572-93-2)

T 0156 hydrochloride is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5). T 0156 exhibits higher selectivity than sildenafil (IC50 = 0.23, 56...

FR-229934
(CAS: 799841-02-4)

FR-229934 is a Type 5 cyclic nucleotide phosphodiesterase inhibitor. In Feb 2008, preclinical for Erectile dysfunction in Japan was discontinued.

CAS 224785-90-4 Vardenafil HCl Trihydrate

Vardenafil HCl Trihydrate
(CAS: 224785-90-4)

Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively. Vardenafil was co-marketed by Bayer Pharmaceu...

CAS 58-32-2 Dipyridamole

Dipyridamole
(CAS: 58-32-2)

Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.

CAS 489-32-7 Icariin

Icariin
(CAS: 489-32-7)

Icariin is a flavonol glycoside and a PDE5 inhibitor (IC50 = 5.9 μM) with 67-fold selectivity for PDE5 over PDE4. It exhibits antioxidant and anticancer activit...

CAS 189940-24-7 Mesopram

Mesopram
(CAS: 189940-24-7)

Mesopram is an orally active, selective phosphodiesterase (PDE) 4 inhibitor. In vitro, mesopram selectively inhibits the activity of type 1 helper T (Th1) cells...

CAS 119615-63-3 Olprinone Hydrochloride

Olprinone Hydrochloride
(CAS: 119615-63-3)

Olprinone is a selective phosphodiesterase 3 (PDE3) inhibitor. Olprinone is used as cardiotonic agent with positive inotropic and vasodilating effects. Olprinon...

CHF-6001
(CAS: 1239278-59-1)

This active molecular is a Type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor originated by Chiesi Farmaceutici with IC50 value of 0.026 ± 0.006 nM. CH...

CAS 611-59-6 Paraxanthine

Paraxanthine
(CAS: 611-59-6)

Paraxanthine is a metabolite of caffeine, and also acts as an inhibitor of phosphodiesterase 9 (PDE9) and an antagonist of adenosine receptors A1 and A2 (Kis = ...

CAS 99519-84-3 L-651,582

L-651,582
(CAS: 99519-84-3)

L-651,582 is a novel inhibitor of both cAMP-phosphodiesterases and GMP-phosphodiesterases. It is also an orally active calcium channel blocker. It prevents oxid...

CAS 1305116-67-9 PF 04671536 hydrochloride

PF 04671536 hydrochloride
(CAS: 1305116-67-9)

PF 04671536 is a highly potent and selective inhibitor of phosphodiesterase 8B (PDE8B) phosphodiesterase 8A (PDE8A) (IC50= 1.3 and 1.9 nM, respectively), with s...

CAS 257892-33-4 AWD 12-281

AWD 12-281
(CAS: 257892-33-4)

AWD 12-281 is a strong selective phosphodiesterase 4 (PDE4) inhibitor which has potent effects in models of lung inflammation using inhalative administration.

CAS 77671-31-9 Enoximone

Enoximone
(CAS: 77671-31-9)

Enoximone is a selective phosphodiesterase III (PDE3) inhibitor. It can be used for the treatment of heart failure.

CAS 73963-72-1 Cilostazol

Cilostazol
(CAS: 73963-72-1)

Cilostazol is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.

CAS 85416-75-7 (R)-(-)-Rolipram

(R)-(-)-Rolipram
(CAS: 85416-75-7)

(R)-(-)-Rolipram is a potent and cAMP-specific PDE4 inhibitor. It is 2.5-fold more potent than (+)-rolipram in inhibiting membrane-bound PDE 4.

CAS 171599-83-0 Sildenafil Citrate

Sildenafil Citrate
(CAS: 171599-83-0)

Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective tr...

CAS 268203-93-6 Udenafil

Udenafil
(CAS: 268203-93-6)

Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ...

PDE10-IN-1 is a potent PDE10-IN-1 inhibi
(CAS: 1516896-09-5)

PDE10-IN-1 is a potent PDE10-IN-1 inhibitor which can be used to treat CNS disorders and metabolic disorders.

CAS 3321-06-0 Denaverine hydrochloride

Denaverine hydrochloride
(CAS: 3321-06-0)

Denaverine hydrochloride is a phosphodiesterase inhibitor.Denaverine hydrochloride is applied in relaxation and delatation of birth canal in animals and spasms ...

CAS 898563-00-3 TP-10

TP-10
(CAS: 898563-00-3)

TP-10 is a PDE10A inhibitor with IC50 of 0.8 nM. It has extremely potent PDE10A inhibitory activity and high selectivity against other PDEs. It is active in the...

Chemical Structure

CAS 68475-42-3 Anagrelide

Quick Inquiry

Verification code

Featured Items